Seth Loring Harrison - Net Worth and Insider Trading

Seth Loring Harrison Net Worth

The estimated net worth of Seth Loring Harrison is at least $251 Million dollars as of 2024-11-13. Seth Loring Harrison is the Director, 10% Owner of Stoke Therapeutics Inc and owns about 17,161,713 shares of Stoke Therapeutics Inc (STOK) stock worth over $234 Million. Seth Loring Harrison is the Director of Akero Therapeutics Inc and owns about 284,364 shares of Akero Therapeutics Inc (AKRO) stock worth over $9 Million. Seth Loring Harrison is also the Director of Heartware International Inc and owns about 139,143 shares of Heartware International Inc (HTWR) stock worth over $8 Million. Details can be seen in Seth Loring Harrison's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Seth Loring Harrison has not made any transactions after 2022-11-30 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Seth Loring Harrison

Seth Loring Harrison Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Seth Loring Harrison owns 6 companies in total, including Akero Therapeutics Inc (AKRO) , Stoke Therapeutics Inc (STOK) , and Heartware International Inc (HTWR) among others .

Click here to see the complete history of Seth Loring Harrison’s form 4 insider trades.

Insider Ownership Summary of Seth Loring Harrison

Ticker	Comapny	Transaction Date	Type of Owner
AKRO	Akero Therapeutics Inc	2022-11-30	director
STOK	Stoke Therapeutics Inc	2020-11-24	director & 10 percent owner
HTWR	Heartware International Inc	2016-08-23	director
		2014-09-16	director & 10 percent owner
		2015-10-14	director & 10 percent owner
		2013-11-25	10 percent owner

Seth Loring Harrison Latest Holdings Summary

Seth Loring Harrison currently owns a total of 3 stocks. Among these stocks, Seth Loring Harrison owns 17,161,713 shares of Stoke Therapeutics Inc (STOK) as of November 24, 2020, with a value of $234 Million and a weighting of 93.12%. Seth Loring Harrison owns 284,364 shares of Akero Therapeutics Inc (AKRO) as of November 30, 2022, with a value of $9 Million and a weighting of 3.67%. Seth Loring Harrison also owns 139,143 shares of Heartware International Inc (HTWR) as of January 6, 2014, with a value of $8 Million and a weighting of 3.21%.

Latest Holdings of Seth Loring Harrison

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
STOK	Stoke Therapeutics Inc	2020-11-24	17,161,713	13.62	233,742,531
AKRO	Akero Therapeutics Inc	2022-11-30	284,364	32.38	9,207,706
HTWR	Heartware International Inc	2014-01-06	139,143	57.98	8,067,511

Holding Weightings of Seth Loring Harrison

Seth Loring Harrison Form 4 Trading Tracker

According to the SEC Form 4 filings, Seth Loring Harrison has made a total of 1 transactions in Stoke Therapeutics Inc (STOK) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Stoke Therapeutics Inc is the acquisition of 375,000 shares on November 24, 2020, which cost Seth Loring Harrison around $15 Million.

According to the SEC Form 4 filings, Seth Loring Harrison has made a total of 4 transactions in Akero Therapeutics Inc (AKRO) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in Akero Therapeutics Inc is the sale of 23,131 shares on November 30, 2022, which brought Seth Loring Harrison around $1 Million.

According to the SEC Form 4 filings, Seth Loring Harrison has made a total of 0 transactions in Heartware International Inc (HTWR) over the past 5 years. The most-recent trade in Heartware International Inc is the sale of 7,909 shares on January 6, 2014, which brought Seth Loring Harrison around $785,285.

Insider Trading History of Seth Loring Harrison

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Seth Loring Harrison Trading Performance

GuruFocus tracks the stock performance after each of Seth Loring Harrison's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Seth Loring Harrison is -1.56%. GuruFocus also compares Seth Loring Harrison's trading performance to market benchmark return within the same time period. The performance of stocks bought by Seth Loring Harrison within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Seth Loring Harrison's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Seth Loring Harrison

Average Return

Average return per transaction

Outperforming Transactions

1 out of 4 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	5.62
Relative Return to S&P 500(%)	2.93

Seth Loring Harrison Ownership Network

Ownership Network List of Seth Loring Harrison

No Data

Ownership Network Relation of Seth Loring Harrison

Seth Loring Harrison Owned Company Details

What does Akero Therapeutics Inc do?

Who are the key executives at Akero Therapeutics Inc?

Seth Loring Harrison is the director of Akero Therapeutics Inc. Other key executives at Akero Therapeutics Inc include Chief Development Officer Catriona Yale , director & President & CEO Andrew Cheng , and Chief Operating Officer Jonathan Young .

Akero Therapeutics Inc (AKRO) Insider Trades Summary

Over the past 18 months, Seth Loring Harrison made no insider transaction in Akero Therapeutics Inc (AKRO). Other recent insider transactions involving Akero Therapeutics Inc (AKRO) include a net sale of 171,998 shares made by Jonathan Young , a net sale of 150,584 shares made by Catriona Yale , and a net sale of 443,502 shares made by Andrew Cheng .

In summary, during the past 3 months, insiders sold 488,023 shares of Akero Therapeutics Inc (AKRO) in total and bought 0 shares, with a net sale of 488,023 shares. During the past 18 months, 1,237,763 shares of Akero Therapeutics Inc (AKRO) were sold and 1,320,000 shares were bought by its insiders, resulting in a net purchase of 82,237 shares.

Akero Therapeutics Inc (AKRO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akero Therapeutics Inc Insider Transactions

No Available Data

What does Stoke Therapeutics Inc do?

Who are the key executives at Stoke Therapeutics Inc?

Seth Loring Harrison is the director & 10 percent owner of Stoke Therapeutics Inc. Other key executives at Stoke Therapeutics Inc include Chief Medical Officer Barry Ticho , 10 percent owner Skorpios Trust , and COO & CBO Huw M. Nash .

Stoke Therapeutics Inc (STOK) Insider Trades Summary

Over the past 18 months, Seth Loring Harrison made no insider transaction in Stoke Therapeutics Inc (STOK). Other recent insider transactions involving Stoke Therapeutics Inc (STOK) include a net sale of 134,116 shares made by Barry Ticho , a net sale of 18,022 shares made by Jonathan Allan , and a net sale of 56,616 shares made by Huw M. Nash .

In summary, during the past 3 months, insiders sold 1,967,500 shares of Stoke Therapeutics Inc (STOK) in total and bought 0 shares, with a net sale of 1,967,500 shares. During the past 18 months, 5,803,870 shares of Stoke Therapeutics Inc (STOK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,803,870 shares.

Stoke Therapeutics Inc (STOK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Stoke Therapeutics Inc Insider Transactions

No Available Data

What does Heartware International Inc do?

Who are the key executives at Heartware International Inc?

Seth Loring Harrison is the director of Heartware International Inc. Other key executives at Heartware International Inc include director & President & Chief Exec Officer Douglas Evan Godshall , 10 percent owner Adage Capital Partners Gp, L.l.c. , and 10 percent owner Adage Capital Partners, L.p. .

Heartware International Inc (HTWR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Heartware International Inc (HTWR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Heartware International Inc (HTWR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Heartware International Inc (HTWR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Heartware International Inc Insider Transactions

No Available Data

What does Eledon Pharmaceuticals Inc do?

Who are the key executives at Eledon Pharmaceuticals Inc?

Seth Loring Harrison is the director & 10 percent owner of Eledon Pharmaceuticals Inc. Other key executives at Eledon Pharmaceuticals Inc include other: See Explanation of Responses Biotechnology Value Fund L P , director & See Remarks Steven Perrin , and director & Chief Executive Officer David-alexandre C Gros .

Eledon Pharmaceuticals Inc (ELDN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Eledon Pharmaceuticals Inc (ELDN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eledon Pharmaceuticals Inc (ELDN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Eledon Pharmaceuticals Inc (ELDN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eledon Pharmaceuticals Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Seth Loring Harrison is the director & 10 percent owner of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Interim CFO Christopher Ryan Sullivan .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Seth Loring Harrison made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 74,840 shares made by Caissa Capital Management Ltd. , a net sale of 3,683,542 shares made by Armistice Capital Master Fund Ltd. , and a net purchase of 4,000 shares made by Garry Arthur Neil .

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 15,348 shares of Avalo Therapeutics Inc (AVTX) were sold and 331 shares were bought by its insiders, resulting in a net sale of 15,017 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does Titan Pharmaceuticals Inc do?

Who are the key executives at Titan Pharmaceuticals Inc?

Seth Loring Harrison is the 10 percent owner of Titan Pharmaceuticals Inc. Other key executives at Titan Pharmaceuticals Inc include 10 percent owner Seow Gim Shen , 10 percent owner Sire Group Ltd. , and director & President and COO Katherine Beebe .

Titan Pharmaceuticals Inc (TTNP) Insider Trades Summary

Over the past 18 months, Seth Loring Harrison made no insider transaction in Titan Pharmaceuticals Inc (TTNP). Other recent insider transactions involving Titan Pharmaceuticals Inc (TTNP) include a net sale of 7,495,936 shares made by David E. Lazar ,

In summary, during the past 3 months, insiders sold 0 shares of Titan Pharmaceuticals Inc (TTNP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 374,797 shares of Titan Pharmaceuticals Inc (TTNP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 374,797 shares.

Titan Pharmaceuticals Inc (TTNP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Titan Pharmaceuticals Inc Insider Transactions

No Available Data

Seth Loring Harrison Mailing Address

Above is the net worth, insider trading, and ownership report for Seth Loring Harrison. You might contact Seth Loring Harrison via mailing address: 230 Park Avenue, Suite 2800, New York Ny 10169.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.